Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAPGEF3 | O95398 | 6/20 | 0.50 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.47 |
| ▸ | HTR3B | O95264 | 2/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbonyl Cyanide M-Chlorophenylhydrazone SCHEMBL379195 | 0.83 | MAPT (1.00) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| Carbonyl Cyanide M-Chlorophenylhydrazone SCHEMBL29353613 | 0.83 | MAPT (1.00) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL12648701 | 0.81 | MAPT (0.66) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL9865909 | 0.77 | MAPT (0.76) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL9868037 | 0.77 | MAPT (0.76) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL9867790 | 0.76 | MAPT (0.70) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL3678595 | 0.76 | MAPT (0.70) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL9868710 | 0.74 | MAPT (0.67) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL9868712 | 0.74 | MAPT (0.67) | MAPTSMN1; SMN2KMT2AMEN1TDP1 | |
| Carbonyl Cyanide M-Chlorophenylhydrazone SCHEMBL28977410 | 0.73 | MAPT (0.76) | MAPTSMN1; SMN2KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12214000-B2 | Human uterine cervical stem cell population and uses thereof | GISTEM RESEARCH S.L. (ES) | 2025-02-04 | — | — | US | disclosed |
| US-20210299184-A1 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | GISTEM RESEARCH S.L. (ES) | 2021-09-30 | — | — | US | disclosed |
| US-20160000835-A1 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | GISTEM RESEARCH S.L. (ES) | 2016-01-07 | — | — | US | disclosed |
| WO-2014128291-A1 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | FUNDACION PARA LA INVESTIGACION CON CELULAS MADRE UTERINAS (ES) | 2014-08-28 | — | — | WO | disclosed |
| EP-1553948-B1 | COMBINATION OF IMATNIB AND A HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT OF LEUKEMIA | UNIV VIRGINIA COMMONWEALTH (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7642051-B2 | Induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (also called adenine nucleotide translocase or ADP/ATP carrier) | INSTITUT PASTEUR (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090264439-A1 | Combination of a) N--4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia | DENT PAUL | 2009-10-22 | — | — | US | disclosed |
| EP-1370572-B1 | MITOCHONDRIAL MEMBRANE PERMEABILIZATION BY HIV-1 VPR AND METHODS OF SCREENING | PASTEUR INSTITUT (FR) | 2008-11-26 | — | — | EP | disclosed |
| US-7056735-B2 | Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) | INSTITUT PASTEUR (FR) | 2006-06-06 | — | — | US | disclosed |
| US-20060100140-A1 | Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia | NOVARTIS AG (CH) | 2006-05-11 | — | — | US | disclosed |
| US-20060052285-A1 | Mechanism of mitochondrial membrane permeabilization by HIV-1 VPR, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT | INSTITUT PASTEUR (FR) | 2006-03-09 | — | — | US | disclosed |
| US-20040072146-A1 | Mechanism of mitochondrial membrane permeabilization by HIV-1 Vpr, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT | UNIVERSITE DE TECHNOLOGIE DE COMPIEGNE (FR) | 2004-04-15 | — | — | US | disclosed |
| US-20020068273-A1 | Mimetics and inhibitors of the interaction between Vpr (HIV vIral protein of regulation) and ANT (mitochondrial adenine nucleotide translocator) | INSTITUT PASTEUR (FR) | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264439-A1 | Combination of a) N--4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia | HDAC5, HDAC2, HDAC1 | MAPT 3984/4885SMN1; SMN2 2046/4885KMT2A 18/4885 |
| US-20060100140-A1 | Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia | HDAC5, HDAC2, HDAC1 | MAPT 4021/4885SMN1; SMN2 2118/4885KMT2A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.